Literature DB >> 3433304

Interaction of aristolochic acid with Vipera russelli phospholipase A2: its effect on enzymatic and pathological activities.

B S Vishwanath1, T V Gowda.   

Abstract

Aristolochic acid, an alkaloid from the plant Aristolochia species, interacts with the major basic phospholipase A2 from Vipera russelli venom. It is an uncompetitive inhibitor with a Ki of 9.9 X 10(-4)M when phosphatidylcholine is used as substrate. The inhibition of direct and indirect hemolysis is higher compared to the inhibition of phosphatidylcholine hydrolysis. Edema-inducing activity of Vipera russelli phospholipase A2 is inhibited by aristolochic acid when injected either as a mixture or separately. Both i.m. and i.p. administration of aristolochic acid following phospholipase injection are equally effective in inhibiting edema. The alkaloid inhibits the edema-inducing activity as soon as it reaches the site, but does not aid in recovery. Aristolochic acid failed to inhibit other pathological activities of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3433304     DOI: 10.1016/0041-0101(87)90155-3

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  23 in total

1.  Purification and inhibitory profile of phospholipase A2 inhibitors from Australian elapid sera.

Authors:  P G Hains; K W Broady
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

2.  Pharmacologic modulation of D-49 phospholipase A2-induced paw edema in the mouse.

Authors:  W Calhoun; J Yu; A Sung; T T Chau; L A Marshall; B M Weichman; R P Carlson
Journal:  Agents Actions       Date:  1989-06

3.  Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid.

Authors:  B S Vishwanath; A A Fawzy; R C Franson
Journal:  Inflammation       Date:  1988-12       Impact factor: 4.092

4.  Predicting the possibility of two newly isolated phenetheren ring containing compounds from Aristolochia manshuriensis as CDK2 inhibitors.

Authors:  Ali Abdullah Alshatwi; Tarique Noorul Hasan; Naveed Ahmed Syed; Gowhar Shafi
Journal:  Bioinformation       Date:  2011-12-10

5.  Do herbal medicines have potential for managing snake bite envenomation?

Authors:  Y K Gupta; S S Peshin
Journal:  Toxicol Int       Date:  2012-05

6.  Progressive Hemorrhage and Myotoxicity Induced by Echis carinatus Venom in Murine Model: Neutralization by Inhibitor Cocktail of N,N,N',N'-Tetrakis (2-Pyridylmethyl) Ethane-1,2-Diamine and Silymarin.

Authors:  Ankanahalli N Nanjaraj Urs; Chandrasekaran Ramakrishnan; Vikram Joshi; Kanve Nagaraj Suvilesh; Teregowda Veerabasappa Gowda; Devadasan Velmurugan; Bannikuppe Sannanaik Vishwanath
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

7.  Structural Basis for the Inhibition of a Phospholipase A2-Like Toxin by Caffeic and Aristolochic Acids.

Authors:  Carlos A H Fernandes; Fábio Florença Cardoso; Walter G L Cavalcante; Andreimar M Soares; Maeli Dal-Pai; Marcia Gallacci; Marcos R M Fontes
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

Review 8.  Snake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural molecules.

Authors:  B M A Carvalho; J D L Santos; B M Xavier; J R Almeida; L M Resende; W Martins; S Marcussi; S Marangoni; R G Stábeli; L A Calderon; A M Soares; S L Da Silva; D P Marchi-Salvador
Journal:  Biomed Res Int       Date:  2013-09-22       Impact factor: 3.411

9.  Release of ATP from marginal cells in the cochlea of neonatal rats can be induced by changes in extracellular and intracellular ion concentrations.

Authors:  Yating Peng; Jie Chen; Shan He; Jun Yang; Hao Wu
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  In Vitro and In Vivo Evaluation of Polyherbal Formulation against Russell's Viper and Cobra Venom and Screening of Bioactive Components by Docking Studies.

Authors:  G Sakthivel; Amitabha Dey; Kh Nongalleima; Murthy Chavali; R S Rimal Isaac; N Surjit Singh; Lokesh Deb
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.